A set of new pyrimido [5,4-b]indole derivatives that are structurally related to some non-nucleoside HIV-1 reverse transcriptase inhibitors were synthesized and biologically evaluated for their activity as inhibitors of wild and mutant HIV-1 RT types in an 'in vitro' recombinant HIV-1 RT screening assay, as well as anti-infectives in HLT4lacZ-1 IIIB cells. Preliminary structure -activity relationships suggest that activity is promoted by simultaneous substitution in positions 2 and 4, especially when chains of alkyldiamine type are present, and by electron-releasing substituents (methoxy) in positions 7 and 8. The inactivity or the very low activity of title derivatives does not suggest interest in AIDS therapy.
Introduction
Once the HIV virus has entered into the host cell, the transcription process is set off, whereby, starting from viral RNA, the proviral DNA is synthesized which later will integrate into the genome of the cell. This activity is carried out by the reverse transcriptase enzyme, a characteristic enzyme of the retroviruses, and due to its uniqueness it is considered to be a fundamental target for the development of new antiretroviral agents.
With the discovery of non-nucleoside agents such as HEPT [1] or TIBO [2] (Fig. 1) , that are capable of inhibiting this enzyme, a new field has been initiated in anti-AIDS research, revealing a great variety of compounds such as bis(heteroaril)piperazines (BHAPs) [3] , TSAO-T [4] , or alkenyldiarylmethanes (ADAMs) [5] . Delavirdine (U-90152s), a BHAP non-nucleoside reverse transcriptase inhibitor, has recently been approved by the FDA (Fig. 1 ). Although these compounds belong to very different structural groups, their interaction with the enzyme in an allosteric site is a common mechanism [6] .
The good oral bioavailability that the non-nucleoside inhibitors present and the lack of significant toxicities to the active doses have constituted a stimulus for scientific research in an attempt to find more potent and selective compounds.
However, it has been determined that the more specific an antiviral compound in its antiviral action, the faster it should be in the development of virus-drug resistance. Taking into account that the compounds described up to now are highly specific for the reverse transcriptase, the rapid development of resistances can be related to this specific character. Thus, through directed studies of mutagenesis, in which the mutation of a single aminoacid can be unequivocally associated with the appearance of resistant viruses, the role which the aminoacids of positions 100, 103, 106, 138, 181, 188 and 236 of the HIV-1 reverse transcriptase play in the appearance of resistance to compounds TIBO, HEPT, Nevirapine, Pyridinones, TSAO and BHAPs was confirmed [7] [8] [9] (Fig. 1) . reverse transcriptase inhibitors (wild and mutant types) (Fig. 2) .
In their structure, these compounds possess an indolic ring, characteristic of compounds of high activity as antiretrovirals (BHAPs, Fig. 1 ), fusioned with a pyrimidine ring, present in non-nucleoside analogs (TSAO-T, HEPT, Fig. 1 ) as well as in nucleoside analogs such as ddl or ddC (Fig. 3) , up to now the most efficient, along with AZT, in the therapy of AIDS.
Taking as a reference these structures I and II, different modifications have been carried out in order to obtain data which permit the establishment of the opportune structure-activity relationships in this type of compound.
Derivatives I have substituents in position 2, while derivatives II in positions 2 and 4. These substituents have been selected using the structure-activity relationships cited in the bibliography as reference for the different groups of non-nucleoside compounds, especially in the case of the BHAPs [3, 16] and the quinoline derivatives ( Fig. 1) [17] .
Thus, by analogy to the quinoline series, aliphatic amines and heterocyclic rings are selected as substituents. In the case of 2, these substituents are connected directly to position 2 of the pyrimido- [5,4-b] indol-4-one ring. While maintaining these substituents in position 2, different primary alkyldiamines are selected and introduced in position 4, series 4.
Bearing in mind the SAR data in the BHAP series, secondary aliphatic cyclic amines (morpholine, piperidine, phenylpiperazines,...) are selected as substituents in series 6, where they are connected to position 2 by a methylene bridge. For series 8, alkyldiamines and secondary aliphatic cyclic amines are introduced simultaneously in position 4.
The increase in activity observed in the BHAP series when electrodonor groups are introduced in the indole ring lead us to introduce the methoxy substituent in positions 7 and 8 of the pyrimido [5,4-b] indole ring.
Chemistry
The synthesis of the compounds described in the present work has been carried out according to Scheme 1. The starting products, ethyl 3-aminoindol-2-carboxylate (1a) and ethyl 3-amino-2-carboxylate-5,6-Certain mutations are related to the use of specific compounds; thus, the substitution of a proline in position 236 by a leucine (mutant type P236L) offers resistance to the BHAPs; other mutations, such as the substitution of a tirosine in position 181 by a cysteine (mutant type Y181C), appear after treatments with TIBO, HEPT, Nevirapine, Pyridinones and BHAPs, among others, observing, in addition, the existence of crossed resistances among the majority of the nucleoside inhibitors [10, 11] .
It was also observed that, within a determined type of non-nucleoside inhibitor, small modifications in their structures can increase and even restore the activity of the new resulting compounds against the resistant HIV-1 strains [12] .
Taking into consideration all of the aforementioned, and within the research carried out on new anti-AIDS agents by our team [13 -15] , we present the synthesis and preliminary study of new pyrimido [5,4-b] indol-4-one (I) and pyrimido [5,4-b] indole (II) analogs as HIV-1 
Biology
Initially, the enzyme inhibitory activity of each compound was evaluated in an in vitro recombinant HIV-1 RT wild type screening assay [21] [22] [23] , at a concentration of 5-50 mM. The compounds whose inhibitory activities were lower than 50% at 50 mM were considered inactive. The active compounds were subsequently evaluated as inhibitors of the mutant HIV-1 RT Y181C enzyme type. Finally, these selected compounds were assayed as anti-infectives in HLT4lacZ-1 cells, and their potential toxicity was evaluated simultaneously [24, 25] . The data corresponding to the active products are shown in Table 3 . The compounds that do not appear in Table 3 were considered inactive.
Discussion
From the initial biological activity data obtained in the in vitro inhibition assay of HIV-1 RT wild type, the following observations can be proposed: 1. The presence of an oxo substituent in position 4 of the pyrimido [5,4-b] indole ring is unfavorable for activity. All the analogs of series 2 and 6 studied were inactive in this assay. 2. The presence of a methylene bridge connecting amine substituents in position 2 provokes a notable decrease in activity. The analogs of series 6 and 8 are also inactive. 3. The simultaneous substitution in positions 2 and 4 is favorable for activity, especially when chains of alkyldiamine type are present. In this way, the active products are included in series 4 ( Table 3 ). 4. The introduction of the methoxyl groups at positions 7 and 8 is beneficial; in general, an increase in activity is observed. In this way, compounds 4e (IC 50 = 37.0 mM), 4i (IC 50 = 29.2 mM), 4j (IC 50 = 37.8 mM), 4m (IC 50 = 69.4 mM) and 4t (IC 50 = 34.1 mM) were selected; they are now being studied as inhibitors of the mutant HIV-1 RT Y181C enzyme. The derivatives 4e, 4i and 4j show an activity which is similar to that found against the wild type; no significant differences were found among the IC 50 values for the mutant and wild types. In the case of the derivatives 4m and 4t, a notable decrease in activity against the mutant type is observed.
As an initial approximation, it could be said that the presence of an electrodonor group in positions 7 and 8 and the presence of either a system which is rich in p electrons (furane ring) or an electrodonor group (dimethylamine) in position 2, is favorable for activity against the mutant type. On the contrary, the absence of methoxy substituents in the indole ring and the presence of a heteroaromatic ring deficient in p electrons (pyridine ring) in position 2 leads to compounds dimethoxyindole (1b), were synthesized with high yield using previously described methods [18, 19] . The condensation of 1 with the appropriate nitriles, in a dry dioxane medium and under a flow of HCl (g), gave the corresponding 3,4-dihydro-5H-pyrimido [5,4-b] indol-4-ones (2, Table 1 ). The treatment of these compounds 2 with POCl 3 and dry dioxane at reflux temperature leads to 4-chloro-5H-pyrimido [5,4-b] indoles (3, Table 2 ). By reaction of these compounds with different primary or secondary amines, in the presence of sodium carbonate in refluxing ethanol or dioxane, compounds 4 were synthesized ( Table 2) . Application of the method of Shishoo et al. [20] for the obtainment of highly functional pyrimidine rings in a single step allows us to synthesize 2-chloromethyl-5H-3,4-dihydropyrimido [5,4-b] indol-4-one (5), by reaction of 1a with chloroacetonitrile, with dry dioxane under a flow of HCl (g). The reaction of 5 with the appropriate secondary amines, with ethanol as the solvent and with sodium carbonate, leads to compounds 6 ( Table 1 ). The oxygen in position 4 of compounds 6 can be substituted by chloro, as in the preceding case, through reaction with POCl 3 , in refluxing dry dioxane, thereby obtaining derivatives 7 ( Table 2 ). The reaction of the last compounds with the selected amines leads to the corresponding derivatives 8 ( Table 2) . Table 1 Physical constants of 3,4-dihydro-5H-pyrimido [5,4-b] that, although they possess activity against the wild type, they lose it against the mutant type.
The interpretation of the results obtained in the assay for determining the anti-infective activity of these compounds is difficult, due to the high cytotoxicity that they show: unfortunately, the anti-infective effective doses are found to be very near the cytotoxic doses. As the described compounds show low potency against HIV-1 infected cells, no molecular modeling studies have been performed, so we do not know whether the butterfly-like model matches with these compounds [26] .
The biological data obtained confirm the interest that these new derivatives could have in the field of anti-AIDS therapy; however, due to the high cytotoxicity shown by these derivatives, new structural modifications are now being proposed in this type of nucleus. These modifications could permit the increase of inhibitory activity on the HIV-1 RT mutant types, decreasing the toxic effects until an adequate safety margin is reached.
Experimental protocols

Chemistry
General laboratory chemicals were purchased from Merck, Sigma, Janssen, and Scharlau.
All the new compounds were characterized by elemental analysis, IR and 1 H NMR. The IR spectra are recorded on a Perkin-Elmer FT 681 using KBr pellets. The 1 H NMR spectra are obtained on a Bruker AC-200E (200 MHz) instrument with Me 4 Si as the internal standard, and at a concentration of approximately 0.1 g/ml. The mass spectra were obtained on a Hewlett-Packard HP-5890 (GC/HPLC/DIP) instrument. All spectra were consistent with assigned structures. Thin layer chromatography was performed on aluminum sheets precoated with silica gel (HF 254, Merck). The developed chromatograms were viewed under UV light or iodine revelation. Melting points were determined on a Mettler FP82 hot stage apparatus equipped with a FP800/FP80 processor and an Olympus A flow of HCl (g) was passed through a mixture of 1 (50 mmol), the appropriate nitrile (120 mmol) and dry dioxane (60 ml), with magnetic stirring and maintained at 0°C for 9-12 h. The mixture was then set aside for 12 h at room temperature (r.t.). The mixture was poured over ice (50 g) and then neutralized with 10% NH 4 OH. The solid that precipitated was isolated by filtration, dried and purified. In this way, compounds 2a, 2c, 2e and 2g were synthesized from 1a, and compounds 2b, 2d, 2f and 2h were synthesized from 1b (Table 1 ).
General procedure for the synthesis of 4-chloropyrimido[5,4-b]indoles, 2-substituted (3)
A mixture of 2 (24 mmol) and POCl 3 (50 ml) was refluxed with magnetic stirring for 8-10 h. The excess reagent was eliminated by vacuum evaporation. 10% NH 4 OH was added over the residue, until neutralization was attained. The solid obtained was isolated by filtration, washed with abundant H 2 O, dried and recrystallized. If the compound is described as hydrochloride (3c, 3d and 3f), this was obtained by dissolving the solid isolated before recrystallization in AcOEt (100 ml). The solution was dried over Na 2 SO 4 and filtered. 35% HCl (3 ml) was added over the solution with stirring and the solid obtained was filtered, dried and recrystallized (Table 2).
General procedure for the synthesis of 4-aminopyrimido[5,4-b]indoles, 2-substituted (4)
A mixture of 3 (4 mmol), the corresponding amine (15 mmol), sodium carbonate (7 mmol) and the appropriate solvent (dioxane, 40-50 ml; ethanol, 40 ml) was refluxed with constant stirring for 20-30 h. The mixture was then poured over ice-cold water (200 ml). The solid obtained was washed with abundant H 2 O, dried and recrystallized. In this way, compounds 4a-c were synthesized from 3a, compounds 4e-g from 3b, com- a % inhibition at 50 mM (n = 3-5). b Concentration-activity curves are carried out with four or more concentrations of test compounds; IC 50 values are calculated from log curve. c % inhibition at 100 mM (n= 3-5).
pounds 4h-j from 3d, compounds 4k-p from 3e, compounds 4q-s from 3f, compounds 4t-v from 3g and compounds 4w-y from 3h (Table 2).
7,8-Dimethoxy-4-N-[2-(N,N-dimethylamino)]-ethylamino-2-(2%-furyl)pyrimido[5,4-b]indole (4e)
From 3b and 2-(N,N-dimethylamino)ethylamine. As white powder. 5.1.12. General procedure for the synthesis of 2-(amino)methyl-3,4-dihydropyrimido [5,4-b] indol-4-ones (6) A mixture of 5 (2.5 g, 11 mmol), the appropriate amine (25 mmol), sodium carbonate (15 mmol) and EtOH (60 ml) was refluxed with magnetic stirring for 3 -8 h. The mixture was poured over cold H 2 O (200 ml). When a solid appeared, it was filtered, washed with abundant H 2 O, dried and purified. When an oily residue appeared, it was extracted with ethyl acetate (3 × 25 ml). The organic extracts were dried with Na 2 SO 4 and the solvent was eliminated under reduced pressure. The solid obtained was dried and recrystallized. In this way compounds 6a-i were obtained (Table 1) .
5.1.13. General procedure for the synthesis of 2-(amino)methyl-4-chloropyrimido [5,4-b] indole (7) A mixture of 6 (6.6 mmol), POCl 3 (15 ml) and dry dioxane (20 ml) was refluxed with stirring for 18 h. The solvent and excess reagent were eliminated under reduced pressure. Dioxane (10 ml) was poured over the residue and the mixture was stirred. The solid obtained was filtered, dried and purified. If the compound is described as hydrochloride, this was obtained by dissolving the solid isolated in AcOEt (50 ml). The solution was dried over Na 2 SO 4 and filtered. 35% HCl (2 ml) was added over the solution with stirring and the solid obtained was filtered, dried and recrystallized. In this way compound 7a (hydrochloride) was synthesized from 6b, compound 7b from 6d and compound 7c from 6e (Table 2 ).
5.1.14. General procedure for the 4-amino-2-(amino)methylpyrimido [5,4-b] indoles (8) A mixture of 7 (3.3 mmol), the appropriate amine (15 mmol), sodium carbonate (6.67 mmol) and dioxane (40 ml) was refluxed with stirring for 20 -30 h. The mixture was poured over ice-cold H 2 O (200 ml). The solid obtained was filtered, washed with abundant H 2 O, dried and recrystallized. In this way, compounds 8a-f were synthesized from 7a and compounds 8g-i were synthesized from 7c (Table 2).
Pharmacology
Poly-rA, oligo(dT) 10 and deoxythymidine triphosphate (dTTP) were obtained from Pharmacia LKB Biotechnology Inc. [
35 S]-dTTPa was purchased from Amersham and DL-dithiothreitol was purchased from Sigma. Nonidet P-40 was obtained from BoehringerMannheim. The scintillation mixture used was Biogreen-11 which was obtained from Scharlau. Glass microfiber filters (Filtermats) were purchased from Skatron Instruments.
U-90152s was kindly provided by the Upjohn Company, Kalamazoo, USA. Recombinant HIV-1 reverse transcriptase (p66), wild and mutant types, purified according to previously reported methods [17] [18] [19] , were also kindly provided by the Upjohn Company. Molt 3/HIV-1 IIIB infected cells were kindly provided by Professor F. Barin and Dr B. Janvier from Université François Rabelais, Tours France; HLT4lacZ-1 cells were kindly provided by Dr S. Saragosti from Hô pital Cochin, Paris, France.
Re6erse transcriptase assay
Enzyme activity was measured in a total volume of 50 ml using a standard reaction mixture containing 50 mM Tris-HCl (pH 8.3), 20 mM DL-dithiothreitol, 60 mM NaCl, 0.05% Nonidet P-40, 10 mM MgCl 2 , 10 mg/ml poly-rA, 5 mg/ml oligo(dt) 10 and 10 mM [
35 S]-dTTPa (0.2 Ci/mmol). The mixture was pre-incubated at 37°C for 2 min and the reaction was initiated by adding the enzyme. Reaction was stopped after 10 min with 50 ml of ice-cold 10% trichloroacetic acid. The insoluble material was collected on glass microfiber filters with a Skatron cell harvester and extensively washed with 5% trichloroacetic acid. Filters were dried in a microwave oven for 2 min, transferred to scintillation vials with 3 ml of cocktail and counted in a liquid scintillation counter. All compounds tested were solubilized in pure DMSO, diluted in water and assayed, maintaining the final concentration of DMSO at 0.5% (v/v).
Cell cultures
HIV-1 IIIB chronically infected Molt-3 cells (Molt-3/ HIV-1 IIIB ) were cultured at 37°C with 5% CO 2 in RPMI 1640 (Gibco) supplemented with 20% FCS (foetal calf serum, Flow), 1% penicillin/streptomycin (Gibco), and 1% anti-PPLO (Gibco).
HT4lacZ-1 cells were cultured in DMEM (Dulbecco's modification of Eagle medium, ICN Flow) supplemented with 2 mM L-glutamine (Gibco), 10% FCS (Flow) and 1% penicillin/streptomycin (Gibco).
Titration of the virus was carried out by means of syncytium formation assay, co-cultivating serial dilutions from viral stocks with uninfected HLT4lacZ-1. The concentration of the virus which caused 100-150 syncytia per well was used for the infection inhibition assays.
Syncytia formation assay
The characteristics and use of HLT4lacZ-1 cells have been described previously [20] . We have adapted their use to perform a quantitative syncytia assay in 96-well plates in order to quantify the inhibitory activity of the synthesized products.
Briefly, 10 000 cells (200 ml)/well were plated the day before the assay. On the following day, the medium was removed and 100 ml of product solution and 100 ml of diluted virus were added. Controls with no product were also made. On the third day of post-infection, the medium was removed and the cells were fixed for 5 min at r.t. with 200 ml of a PBS solution containing 1% formaldehyde (Merck) and 0.2% glutaraldehyde (Merck). After two washes with 0.9% NaCl (Merck), the cells were incubated for 1 h at 37°C with 200 ml of a reaction mixture containing X-gal (5-bromo-4-chloro-3-indolyl-b-D-galactopyranoside, Boehringer -Mannheim) (400 mg/ml), 4 mM potassium ferrocyanide (Merck), and 2 nM MgCl 2 (Merck) in PBS. After two washes, 100 ml of 0.9% NaCl were added per well. The plates were examined under the microscope and only syncytia with three or more blue nuclei were counted in the entire well.
Cell toxicity
Viability of HLT4lacZ-1 cells was evaluated in the presence of the synthesized products using a modified cell lytic assay described previously [21] . It was performed in parallel with the syncytia formation assay.
A total of 200 ml of medium containing different concentrations of the products or medium (control wells) were added to 10 000 HLT4lacZ-1 cells plated the day before. On the third day, the wells were washed three times with PBs, and cell lysis was detected by staining the plate for 10 min at r.t., with 20 ml/well of a methanol/water (1:4 v/v) solution containing 0.5% crystal violet (Merck). Controls of wells have been prepared by staining the plates without cells (blank wells). Three washes were carried out by immersion of the plates in PBS, changing the PBS of the container each time. The plates were wiped and 100 ml/well of 0.1% SDS (sodium dodecyl sulfate, Sigma) were added. After complete desegregation of the cell membranes, the O.D. at 540 nm was read in a Titertek Multiskan II autoreader (Flow) and the percentage of viability (% V) was calculated.
